BTS Clinical Statement on pulmonary sarcoidosis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
This British Thoracic Society (BTS) Clinical Statement addresses the diagnosis, evaluation and management of pulmonary sarcoidosis, with each section summarised with key clinical practice points. In an era in which medical practice is increasingly determined by evidence-based guidelines, it must be acknowledged from the outset that current evidence in sarcoidosis, especially with regard to treatment, is weak. Thus, a number of the conclusions in this Statement are based on expert opinion and accumulated clinical experience. The diagnosis of pulmonary sarcoidosis is often challenging, with ongoing evolution in clinician views on the need for a tissue diagnosis. Historically, a biopsy diagnosis was considered mandatory and we provide guidance on when to offer bronchoscopy and which bronchoscopic procedure to perform. We also stress that decisions made by individual patients to decline bronchoscopy, when there is a highly probable but not definite clinical diagnosis, should be supported in most cases, with careful subsequent monitoring. The document includes sections on the diagnosis of cardiac sarcoidosis and pulmonary hypertension as either disorder may present to respiratory physicians as ‘symptomatic pulmonary sarcoidosis’. Traditional treatment algorithms and their reported application in the medical literature tend to be based on a ‘one size fits all’ approach and this has often led to over-treatment and major steroid-related comorbidity. However, a great many patients do not need to be treated: the broad indications for initiating therapy are a) a high risk of mortality or disability due to major organ involvement; and b) unacceptable loss of quality of life. In this statement, we focus on the management of pulmonary disease; the management of concurrent cardiac sarcoidosis or pulmonary hypertension requires referral to expert sub-specialist teams. Key pulmonary management considerations are discussed in this statement. Whilst higher dose treatment regimens may be required in high-risk disease, a highly flexible patient-centred approach is essential when treatment is introduced solely for quality of life reasons. In this context, sustained high-dose therapy is usually inappropriate. Patients should be asked to weigh-up treatment benefits against adverse effects before longer-term treatment decisions are made, with the danger of important comorbidities arising from long-term treatment kept carefully in mind. Monitoring must be tailored to specific goals. Fatigue, a highly prevalent and often disabling symptom in sarcoidosis, requires a systematic approach. Above all, we highlight the need for active patient involvement in decision-making and this, in turn, requires attention to clear communication, discussed in the final part of this statement. Finally, it is important to note that in a few areas of diagnosis and management where there was a non-unanimous consensus amongst the statement authors, this is clearly indicated. Scope The Statement covers diagnosis and management of pulmonary sarcoidosis. Reference is also made to diagnosis of cardiac sarcoidosis and pulmonary hypertension as either disorder may present to respiratory physicians as ‘symptomatic pulmonary sarcoidosis’. Other extra pulmonary sarcoidosis diagnoses are not covered by this Statement and it is recommended that specialists with specific sarcoidosis knowledge be consulted when the disease is present outside the chest. Importantly, it may be difficult to identify the true extent of organ involvement leading to underestimation of disease outside the chest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
Self-citationLow-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317
Valeyre, D., Prasse, A., Nunes, H., Uzunhan, Y., Brillet, P.-Y., & Müller-Quernheim, J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60680-7 · Cited by 1,087
Predictors of mortality in pulmonary sarcoidosis
Kirkil, G., Lower, E. E., & Baughman, R. P. (2018) · Chest · doi:10.1016/j.chest.2017.07.008 · Cited by 243
Exogenous cushing’s syndrome and glucocorticoid withdrawal
Hopkins, R. L., & Leinung, M. C. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.013 · Cited by 224
Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself
Dinsen, S., Baslund, B., Klose, M., Rasmussen, A. K., Friis-Hansen, L., Hilsted, L., & Feldt-Rasmussen, U. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.05.014 · Cited by 148
Cited by
Wijsenbeek, M., Suzuki, A., & Maher, T. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01052-2 · Cited by 539
Challenges of Sarcoidosis and Its Management
Drent, M., Crouser, E. D., & Grunewald, J. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2101555 · Cited by 433
Diagnosis and Treatment of Pulmonary Sarcoidosis: A Review
Belperio, J. A., Shaikh, F., Abtin, F. G., Fishbein, M. C., Weigt, S. S., Saggar, R., & Lynch, J. P. (2022) · JAMA · doi:10.1001/jama.2022.1570 · Cited by 191
Metadata
- Authors
- Thillai, M., Atkins, C. P., Crawshaw, A., Hart, S. P., Ho, L.-P., Kouranos, V., Patterson, K. C., Screaton, N. J., Whight, J., & Wells, A. U.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2020-12-02
- Volume
- 76
- Issue
- 1
- Pages
- 4-20
- ISSN
- 0040-6376 (ISSN-L)
- 1468-3296
- OpenAlex
- W3109133775
- Cited by
- 194
- References
- 8
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BTS Clinical Statement on pulmonary sarcoidosis. https://app.cochat.ai/papers/10.1136/thoraxjnl-2019-214348
- The paper
- Thillai, M., Atkins, C. P., Crawshaw, A., Hart, S. P., Ho, L.-P., Kouranos, V., Patterson, K. C., Screaton, N. J., Whight, J., & Wells, A. U. (2021). BTS Clinical Statement on pulmonary sarcoidosis. Thorax. https://doi.org/10.1136/thoraxjnl-2019-214348
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.